​

Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARWR Stock Forecast

Arrowhead Pharmaceuticals stock forecast is as follows: an average price target of $27.74 (represents a 42.62% upside from ARWR’s last price of $19.45) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

ARWR Price Target

The average price target for Arrowhead Pharmaceuticals (ARWR) is $27.74 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $29.97 to $24.00. This represents a potential 42.62% upside from ARWR's last price of $19.45.

ARWR Analyst Ratings

Buy

According to 12 Wall Street analysts, Arrowhead Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ARWR stock is 0 'Strong Buy' (0.00%), 8 'Buy' (66.67%), 4 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Arrowhead Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 29, 2024William PickeringBernstein$24.00$25.81-7.02%23.39%
Nov 27, 2024Keay NakaeLoop Capital Markets$29.97$12.90132.33%54.09%
Sep 03, 2024David LebowitzCitigroup$27.00$22.9117.85%38.82%
Jul 05, 2024Patrick TrucchioH.C. Wainwright$29.97$12.77134.69%54.09%
Jun 05, 2024Andrea TanGoldman Sachs$31.00$25.2922.58%59.38%
May 30, 2024Luca IssiRBC Capital$24.98$11.43118.55%28.43%
Feb 07, 2023RBC Capital$38.46$16.45133.80%97.74%
Feb 07, 2023Piper Sandler$52.00$33.5155.18%167.35%
Dec 06, 2022H.C. Wainwright$44.96$15.75185.46%131.16%
Nov 29, 2022Jefferies$37.47$14.99149.97%92.65%
Nov 29, 2022Morgan Stanley$37.00$28.0032.14%90.23%
Nov 29, 2022Leerink Partners$31.00$28.0010.71%59.38%
Jan 19, 2022Madhu KumarGoldman Sachs$85.00$53.7958.02%337.02%

The latest Arrowhead Pharmaceuticals stock forecast, released on Nov 29, 2024 by William Pickering from Bernstein, set a price target of $24.00, which represents a -7.02% decrease from the stock price at the time of the forecast ($25.81), and a 23.39% increase from ARWR last price ($19.45).

Arrowhead Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts226
Avg Price Target$26.99$26.99$27.82
Last Closing Price$19.45$19.45$19.45
Upside/Downside38.77%38.77%43.03%

In the current month, the average price target of Arrowhead Pharmaceuticals stock is $26.99, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 38.77% increase as opposed to Arrowhead Pharmaceuticals's last price of $19.45. This month's average price target is down 0.00% compared to last quarter, and down -2.98% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 29, 2024BernsteinMarket PerformMarket PerformHold
Nov 27, 2024Piper SandlerOverweightOverweightHold
Nov 27, 2024Chardan CapitalBuyBuyHold
Nov 18, 2024CitigroupNeutralNeutralHold
Oct 14, 2024H.C. WainwrightBuyBuyHold
Sep 04, 2024H.C. WainwrightBuyBuyHold
Sep 03, 2024CitigroupNeutralNeutralHold
Aug 21, 2024Cowen & Co.BuyBuyHold
Aug 15, 2024Piper SandlerOverweightOverweightHold
Jul 05, 2024H.C. WainwrightBuyBuyHold
Jun 05, 2024Goldman SachsNeutralInitialise
May 30, 2024RBC CapitalOutperformOutperformHold
May 24, 2024Piper SandlerOverweightOverweightHold
May 20, 2024CitigroupNeutralNeutralHold
May 13, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Feb 07, 2024RBC CapitalBuyBuyHold
Feb 07, 2024Morgan StanleyUnderperformUnderperformHold
Apr 12, 2023SVB LeerinkMarket PerformOutperformUpgrade
Feb 07, 2023RBC CapitalOutperformOutperformHold
Feb 07, 2023Piper SandlerOverweightOverweightHold
Nov 30, 2022B. Riley SecuritiesBuyBuyHold
Nov 29, 2022JefferiesBuyBuyHold
Nov 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Nov 29, 2022SVB LeerinkMarket PerformMarket PerformHold
Jun 13, 2022H.C. WainwrightBuyBuyHold

Arrowhead Pharmaceuticals's last stock rating was published by Bernstein on Nov 29, 2024. The company gave ARWR a "Market Perform" rating, the same as its previous rate.

Arrowhead Pharmaceuticals Financial Forecast

Arrowhead Pharmaceuticals Revenue Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
Revenue-------$3.55M$16.10M$15.82M$146.27M$62.55M$31.57M$32.41M$151.81M$27.44M$38.28M$45.89M$32.81M$21.30M$7.63M$27.38M$23.53M$29.45M$43.29M$42.70M$48.15M$650.13K$8.99M$43.75K
Avg Forecast$29.99M$24.51M$18.74M$15.49M$55.07M$52.87M$41.97M$33.87M$44.63M$45.42M$45.48M$162.52M$50.30M$45.75M$122.15M$47.81M$42.19M$43.47M$39.42M$106.12M$57.76M$30.42M$22.16M$31.08M$40.98M$54.37M$42.92M$650.00K$13.48M$42.28K
High Forecast$29.99M$24.51M$18.74M$15.49M$111.78M$52.87M$41.97M$68.58M$179.39M$45.42M$45.48M$162.52M$50.30M$45.75M$122.15M$47.81M$42.19M$43.47M$39.42M$106.12M$57.76M$30.42M$22.16M$31.08M$40.98M$54.37M$42.92M$780.00K$16.18M$50.74K
Low Forecast$29.99M$24.51M$18.74M$15.49M$8.58M$52.87M$41.97M$838.37K$3.52M$45.42M$45.48M$162.52M$50.30M$45.75M$122.15M$47.81M$42.19M$43.47M$39.42M$106.12M$57.76M$30.42M$22.16M$31.08M$40.98M$54.37M$42.92M$520.00K$10.79M$33.83K
# Analysts527763451159544755107599913131313151016
Surprise %-------0.10%0.36%0.35%3.22%0.38%0.63%0.71%1.24%0.57%0.91%1.06%0.83%0.20%0.13%0.90%1.06%0.95%1.06%0.79%1.12%1.00%0.67%1.03%

Arrowhead Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $41.97M, with a low forecast of $41.97M, and a high forecast of $41.97M. ARWR's average Quarter revenue forecast represents a 1081.94% increase compared to the company's last Quarter revenue of $3.55M (Dec 23).

Arrowhead Pharmaceuticals EBITDA Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts527763451159544755107599913131313151016
EBITDA-------$-129.06M$-99.87M$-94.95M$55.40M$-42.13M$-83.83M$-70.31M$44.15M$-60.30M$-60.87M$-27.93M$-24.90M$-18.88M$-46.66M$-12.07M$-18.46M$-1.41M$12.96M$21.34M$25.07M$-13.73M$-4.85M$-20.01M
Avg Forecast$-17.74M$-14.50M$-11.09M$-9.17M$-32.58M$-31.28M$-24.83M$-20.04M$-26.41M$-26.87M$-26.91M$-37.59M$-31.36M$-28.53M$-76.17M$-29.82M$-26.31M$-27.11M$-27.39M$-66.17M$-36.02M$-18.97M$-9.57M$-19.38M$-25.55M$-33.90M$18.47M$-13.73M$-6.47M$-21.09M
High Forecast$-17.74M$-14.50M$-11.09M$-9.17M$-5.08M$-31.28M$-24.83M$-495.99K$-2.08M$-26.87M$-26.91M$-30.07M$-31.36M$-28.53M$-76.17M$-29.82M$-26.31M$-27.11M$-21.91M$-66.17M$-36.02M$-18.97M$-7.66M$-19.38M$-25.55M$-33.90M$22.17M$-10.98M$-5.18M$-16.87M
Low Forecast$-17.74M$-14.50M$-11.09M$-9.17M$-66.13M$-31.28M$-24.83M$-40.57M$-106.13M$-26.87M$-26.91M$-45.10M$-31.36M$-28.53M$-76.17M$-29.82M$-26.31M$-27.11M$-32.87M$-66.17M$-36.02M$-18.97M$-11.49M$-19.38M$-25.55M$-33.90M$14.78M$-16.48M$-7.77M$-25.31M
Surprise %-------6.44%3.78%3.53%-2.06%1.12%2.67%2.46%-0.58%2.02%2.31%1.03%0.91%0.29%1.30%0.64%1.93%0.07%-0.51%-0.63%1.36%1.00%0.75%0.95%

5 analysts predict ARWR's average Quarter EBITDA for Jun 23 to be $-26.87M, with a high of $-26.87M and a low of $-26.87M. This is -148.50% lower than Arrowhead Pharmaceuticals's previous annual EBITDA (Mar 23) of $55.40M.

Arrowhead Pharmaceuticals Net Income Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts527763451159544755107599913131313151016
Net Income-------$-132.86M$-109.68M$-102.95M$48.67M$-41.81M$-85.94M$-71.18M$44.37M$-62.87M$-63.37M$-29.92M$-26.82M$-20.73M$-48.43M$-13.61M$-19.84M$-2.67M$11.70M$20.34M$23.90M$-14.88M$-6.04M$-20.82M
Avg Forecast$-141.99M$-152.46M$-159.66M$-158.33M$-120.53M$-65.69M$248.71M$-99.49M$-75.59M$-70.71M$266.00M$-39.19M$-72.53M$-70.62M$284.50M$-55.50M$5.94M$-17.11M$-29.50M$15.06M$12.31M$-14.28M$-10.29M$2.66M$20.40M$35.27M$17.61M$-14.88M$-8.06M$-21.94M
High Forecast$-141.99M$-152.46M$-114.26M$-114.26M$103.31M$-65.69M$298.46M$-36.99M$94.48M$-70.71M$319.21M$-31.35M$-72.53M$-70.62M$341.40M$-55.50M$5.94M$-17.11M$-23.60M$15.06M$12.31M$-14.28M$-8.23M$2.66M$20.40M$35.27M$21.13M$-11.91M$-6.45M$-17.55M
Low Forecast$-141.99M$-152.46M$-196.23M$-191.27M$-285.05M$-65.69M$198.97M$-142.85M$-124.72M$-70.71M$212.80M$-47.03M$-72.53M$-70.62M$227.60M$-55.50M$5.94M$-17.11M$-35.40M$15.06M$12.31M$-14.28M$-12.34M$2.66M$20.40M$35.27M$14.09M$-17.86M$-9.67M$-26.33M
Surprise %-------1.34%1.45%1.46%0.18%1.07%1.18%1.01%0.16%1.13%-10.67%1.75%0.91%-1.38%-3.93%0.95%1.93%-1.00%0.57%0.58%1.36%1.00%0.75%0.95%

Arrowhead Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-70.71M, with a range of $-70.71M to $-70.71M. ARWR's average Quarter net income forecast represents a -245.26% decrease compared to the company's last Quarter net income of $48.67M (Mar 23).

Arrowhead Pharmaceuticals SG&A Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts527763451159544755107599913131313151016
SG&A-------$23.19M$24.17M$23.37M$22.82M$20.98M$33.24M$32.74M$33.86M$24.59M$38.29M$17.86M$16.19M$8.65M$14.27M$10.75M$16.33M$10.79M$10.27M$4.81M$5.33M$3.68M$6.95M$10.48M
Avg Forecast$13.35M$10.91M$8.35M$6.90M$24.52M$23.54M$18.69M$15.08M$19.87M$20.23M$20.25M$15.33M$22.46M$20.43M$54.55M$21.35M$18.84M$19.41M$17.81M$47.39M$25.80M$13.59M$8.47M$13.88M$18.30M$24.28M$3.93M$290.30K$9.27M$18.88K
High Forecast$13.35M$10.91M$8.35M$6.90M$49.77M$23.54M$18.69M$30.54M$79.88M$20.23M$20.25M$18.39M$22.46M$20.43M$54.55M$21.35M$18.84M$19.41M$21.37M$47.39M$25.80M$13.59M$10.16M$13.88M$18.30M$24.28M$4.72M$348.36K$11.12M$22.66K
Low Forecast$13.35M$10.91M$8.35M$6.90M$3.82M$23.54M$18.69M$373.30K$1.57M$20.23M$20.25M$12.26M$22.46M$20.43M$54.55M$21.35M$18.84M$19.41M$14.25M$47.39M$25.80M$13.59M$6.77M$13.88M$18.30M$24.28M$3.14M$232.24K$7.41M$15.11K
Surprise %-------1.54%1.22%1.16%1.13%1.37%1.48%1.60%0.62%1.15%2.03%0.92%0.91%0.18%0.55%0.79%1.93%0.78%0.56%0.20%1.36%12.68%0.75%555.17%

Arrowhead Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $18.69M, based on 4 Wall Street analysts, with a range of $18.69M to $18.69M. The forecast indicates a -19.42% fall compared to ARWR last annual SG&A of $23.19M (Dec 23).

Arrowhead Pharmaceuticals EPS Forecast

Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16
# Analysts527763451159544755107599913131313151016
EPS-------$-1.24$-1.03$-0.96$0.46$-0.39$-0.81$-0.67$0.42$-0.60$-0.61$-0.29$-0.26$-0.20$-0.47$-0.13$-0.20$-0.03$0.12$0.21$0.25$-0.18$-0.08$-0.35
Avg Forecast$-1.14$-1.23$-1.29$-1.27$-0.97$-0.53$-0.47$-0.80$-0.61$-0.57$-0.62$0.37$-0.58$-0.57$0.14$-0.45$0.05$-0.14$0.10$0.12$0.10$-0.12$-0.11$0.02$0.16$0.28$0.20$-0.18$-0.16$-0.39
High Forecast$-1.14$-1.23$-0.92$-0.92$0.83$-0.53$-0.47$-0.30$0.76$-0.57$-0.62$0.37$-0.58$-0.57$0.14$-0.45$0.05$-0.14$0.10$0.12$0.10$-0.12$-0.11$0.02$0.16$0.28$0.20$-0.14$-0.13$-0.31
Low Forecast$-1.14$-1.23$-1.58$-1.54$-2.30$-0.53$-0.47$-1.15$-1.00$-0.57$-0.62$0.37$-0.58$-0.57$0.14$-0.45$0.05$-0.14$0.10$0.12$0.10$-0.12$-0.11$0.02$0.16$0.28$0.20$-0.22$-0.19$-0.47
Surprise %-------1.55%1.69%1.69%-0.74%-1.05%1.39%1.18%2.90%1.34%-12.68%2.11%-2.52%-1.65%-4.75%1.13%1.85%-1.40%0.73%0.74%1.26%1.00%0.50%0.90%

According to 5 Wall Street analysts, Arrowhead Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-0.57, with a low estimate of $-0.57 and a high estimate of $-0.57. This represents a -223.76% decrease compared to ARWR previous annual EPS of $0.46 (Mar 23).

Arrowhead Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CTMXCytomX Therapeutics$1.13$3.47207.08%Buy
ANNXAnnexon$4.88$14.00186.89%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
ASMBAssembly Biosciences$14.28$35.50148.60%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
IONSIonis Pharmaceuticals$37.68$58.3354.80%Buy
WVEWave Life Sciences$14.45$22.1453.22%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
INCYIncyte$69.40$90.1129.84%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
ARWRArrowhead Pharmaceuticals$22.27$27.7424.56%Buy
PRQRProQR Therapeutics$2.94$3.6323.47%Buy

ARWR Forecast FAQ

Is Arrowhead Pharmaceuticals a good buy?

Yes, according to 12 Wall Street analysts, Arrowhead Pharmaceuticals (ARWR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 66.67% of ARWR's total ratings.

What is ARWR's price target?

Arrowhead Pharmaceuticals (ARWR) average price target is $27.74 with a range of $24 to $29.97, implying a 42.62% from its last price of $19.45. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arrowhead Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ARWR stock, the company can go up by 42.62% (from the last price of $19.45 to the average price target of $27.74), up by 54.09% based on the highest stock price target, and up by 23.39% based on the lowest stock price target.

Can Arrowhead Pharmaceuticals stock reach $30?

ARWR's average twelve months analyst stock price target of $27.74 does not support the claim that Arrowhead Pharmaceuticals can reach $30 in the near future.

What is Arrowhead Pharmaceuticals's current price target trend?

2 Wall Street analysts forecast a $26.99 price target for Arrowhead Pharmaceuticals (ARWR) this month, up 38.77% from its last price of $19.45. Compared to the last 3 and 12 months, the average price target increased by 38.77% and increased by 43.03%, respectively.

What are Arrowhead Pharmaceuticals's analysts' financial forecasts?

Arrowhead Pharmaceuticals's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $183.78M (high $275.2M, low $104.27M), average EBITDA is $-109M (high $-61.686M, low $-163M), average net income is $-36.991M (high $299.08M, low $-295M), average SG&A $81.83M (high $122.54M, low $46.43M), and average EPS is $-2.772 (high $-0.467, low $-4.446). ARWR's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $88.74M (high $88.74M, low $88.74M), average EBITDA is $-52.499M (high $-52.499M, low $-52.499M), average net income is $-612M (high $-523M, low $-682M), average SG&A $39.51M (high $39.51M, low $39.51M), and average EPS is $-4.931 (high $-4.211, low $-5.491).

Did the ARWR's actual financial results beat the analysts' financial forecasts?

Based on Arrowhead Pharmaceuticals's last annual report (Sep 2023), the company's revenue was $240.74M, which missed the average analysts forecast of $298.05M by -19.23%. Apple's EBITDA was $-202M, beating the average prediction of $-118M by 71.94%. The company's net income was $-205M, missing the average estimation of $80.52M by -354.93%. Apple's SG&A was $92.55M, beating the average forecast of $75.68M by 22.29%. Lastly, the company's EPS was $-1.92, beating the average prediction of $-1.426 by 34.64%. In terms of the last quarterly report (Dec 2023), Arrowhead Pharmaceuticals's revenue was $3.55M, missing the average analysts' forecast of $33.87M by -89.52%. The company's EBITDA was $-129M, beating the average prediction of $-20.038M by 544.07%. Arrowhead Pharmaceuticals's net income was $-133M, beating the average estimation of $-99.487M by 33.55%. The company's SG&A was $23.19M, beating the average forecast of $15.08M by 53.79%. Lastly, the company's EPS was $-1.24, beating the average prediction of $-0.801 by 54.80%